Attovia Therapeutics (ATTO) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sana Biotechnology is the larger company by market cap ($835.2 million vs $740.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | SANA |
|---|---|---|
| Share price | $16.21 | $2.79 |
| Market cap | $740.01M | $835.22M |
| 1-day change | -0.61% | 0.00% |
| YTD return | — | -31.45% |
| 1-year return | — | -38.41% |
| 5-year return | — | -86.58% |
| EPS (TTM) | $-2.74 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $6.55 |
| 52-week low | $15.48 | $2.61 |
| Distance from 52-week high | -42.11% | -57.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +160.33% | +202.15% |
| Average volume | 457.37K | 3.13M |
| Shares outstanding | 45.65M | 299.36M |
| Employees | 44 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
ATTO vs SANA FAQ
Which is bigger, Attovia Therapeutics or Sana Biotechnology?
Sana Biotechnology (SANA) is larger, with a market capitalization of $835.22M compared with $740.01M for Attovia Therapeutics (ATTO).
Are Attovia Therapeutics and Sana Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.